Ravelcare Ltd

Ravelcare Ltd announced its 8th Annual General Meeting (AGM) scheduled for September 23, 2026, to be held via Video Conferencing. The company also released its Annual Report for FY 2025-26, detailing significant business and financial highlights. Key figures include revenue from operations of ₹2,695.43 Lakhs, a 7.9% increase, and a profit after tax of ₹515.40 Lakhs, resulting in a 19.1% net margin. The company remains debt-free with a strengthened net worth of ₹3,740.84 Lakhs. Ravelcare also highlighted its expansion into new product lines, including Ravel PRO clinical haircare and an upcoming derm-grade skincare range, serving over 27,000 pincodes across India. The company's shares listed on the BSE SME platform on December 8, 2025.

Ravelcare Ltd has announced the launch of its new product line, Ravel PRO, and an upcoming AI diagnostic skincare range. The Ravel PRO line, featuring dermatologist-developed products for specific hair concerns, is now available on major e-commerce and quick-commerce platforms, contributing to approximately 20% incremental revenue in its first month. The AI-led skincare range is slated for launch in H2 FY27. This expansion broadens Ravelcare's market reach from direct-to-consumer personalization to an omni-channel mass market approach. The company aims to leverage its expertise in custom formulations to lead in clinical, concern-led products and technology-driven skincare, positioning for significant growth in FY27 and beyond.

Ravelcare Ltd announced key decisions from its Board of Directors meeting held on August 25, 2026. The company re-appointed Mr. Ayush Varma as Managing Director and Mr. Maheshkumar Varma as Whole-time Director for a three-year term commencing June 20, 2027, subject to shareholder approval. M/s. VTSN & Associates LLP was appointed as the Secretarial Auditor for FY 2026-27. Additionally, the Board approved the shifting of the registered office within Mumbai and announced the 8th Annual General Meeting details. Mr. Vishal Thawani will serve as Scrutinizer for the e-voting process.

Ravelcare Ltd announced key decisions from its Board of Directors meeting held on August 25, 2026. The company approved the re-appointment of Mr. Ayush Varma as Managing Director and Mr. Maheshkumar Varma as Whole-time Director, both for a three-year term commencing June 20, 2027, subject to member approval. M/s. VTSN & Associates LLP was re-appointed as Secretarial Auditors for FY 2026-27. A significant change is the shifting of the company's registered office within Mumbai, effective August 26, 2026. The board also approved the notice for the 8th Annual General Meeting and the Directors' Report for the year ended March 31, 2026.

Ravelcare Ltd announced the re-appointment of Mr. Ayush Varma as Managing Director and Mr. Maheshkumar Varma as Whole-time Director, both for a three-year term effective June 20, 2027, subject to member approval. The company also re-appointed M/s. VTSN & Associates LLP as Secretarial Auditors for FY 2026-27 and approved the shifting of its registered office within Mumbai, effective August 26, 2026. The Board meeting also approved the notice for the 8th Annual General Meeting and the Directors Report for the year ended March 31, 2026.

Ravelcare Ltd reports no deviation or variation in the utilization of funds raised through its Initial Public Offer (IPO) for the year ended March 31, 2026. The company confirms that the funds were utilized as per the objects stated in the Prospectus. This statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on May 30, 2026. Ratan Chandak & Co LLP, Chartered Accountants, have certified the IPO fund utilization as on March 31, 2026, stating that it matches the audited books of accounts.

Ravelcare Ltd's Board of Directors approved the audited financial results for the half year and financial year ended March 31, 2026. The board re-appointed M/s. Mahesh Dhabalia & Co. as Internal Auditors for FY 2026-27. The statutory auditors issued an audit report with an unmodified opinion on the financial results. The board meeting commenced at 8:00 p.m. and concluded at 8:30 p.m.

Ravelcare Ltd's Board of Directors approved the audited financial results for the half year and financial year ended March 31, 2026. The statutory auditors, Ratan Chandak & Co LLP, issued an audit report with an unmodified opinion on these results. Additionally, M/s. Mahesh Dhabalia & Co., Chartered Accountants, were re-appointed as internal auditors for FY 2026-27. The board meeting, held on May 30, 2026, commenced at 8:00 p.m. and concluded at 8:30 p.m.

Ravelcare Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the Audited Financial Results for the half year and financial year ended March 31, 2026. The meeting will also include a review of the Audit Report for the corresponding period. The company's trading window for dealing in shares has been closed since April 1, 2026, and will remain closed until 48 hours after the board meeting concludes.

Ravelcare Ltd, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, has announced the closure of the trading window for 'Designated Persons' and their 'Immediate Relatives'. The closure will be effective from Wednesday, April 01, 2026, and will continue for 48 hours after the announcement of the Audited Financial Results for the half year and year ended on March 31, 2026. The date of the Board Meeting for considering the Audited Financial Results along with the Audit Report of the Company for the same period will be intimated in due course.